Get startedLog in
    Picture of Santhera Pharmaceuticals Holding AG logo

    SANN — Santhera Pharmaceuticals Holding AG News Story

    0.000.00%
    ch flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapMomentum Trap
    All News

    Brief: Santhera: Agamree (Vamorolone) Approved As Treatment For Duchenne Muscular Dystrophy In UK

    Picture of Santhera Pharmaceuticals Holding AG logoSanthera Pharmaceuticals Holding AG
    12/01/2024 06:02
    Jan 12 (Reuters) - Santhera Pharmaceuticals Holding AG
 SANN.S :
    * SANTHERA RECEIVES APPROVAL FOR AGAMREE® (VAMOROLONE) AS A
TREATMENT FOR DUCHENNE MUSCULAR DYSTROPHY IN THE UNITED KINGDOM
    * LAUNCHES OF AGAMREE IN EUROPE, WITH GERMANY TAKING LEAD,
ARE
PLANNED TO START IN Q1-2024

Source text for Eikon:  ID:nGNE89ChVV 
Further company coverage:  SANN.S 

 (Reporting by Berlin Newsroom)
 ((berlin.newsroom@thomsonreuters.com;))

    Recent news on Santhera Pharmaceuticals Holding AG

    See all news